Compare DAWN & PDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DAWN | PDX |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | NY |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 931.2M |
| IPO Year | 2021 | N/A |
| Metric | DAWN | PDX |
|---|---|---|
| Price | $11.33 | $20.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $27.56 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | N/A |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.95% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $133,672,000.00 | N/A |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $52.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.11 | N/A |
| 52 Week Low | $5.64 | $13.52 |
| 52 Week High | $13.20 | $21.05 |
| Indicator | DAWN | PDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 52.23 |
| Support Level | $11.00 | $19.86 |
| Resistance Level | $11.84 | $20.36 |
| Average True Range (ATR) | 0.92 | 0.35 |
| MACD | -0.08 | 0.11 |
| Stochastic Oscillator | 43.75 | 78.95 |
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.